Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 6,552 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert Goeltz II sold 6,552 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $23.38, for a total value of $153,185.76. Following the transaction, the chief financial officer owned 67,924 shares in the company, valued at $1,588,063.12. This trade represents a 8.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Arcus Biosciences Stock Down 2.6%

Shares of RCUS traded down $0.61 on Friday, reaching $23.22. The stock had a trading volume of 1,025,939 shares, compared to its average volume of 1,978,466. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $26.40. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.75 and a beta of 0.78. The company has a 50-day simple moving average of $22.27 and a 200-day simple moving average of $14.98.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The business had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The firm’s quarterly revenue was down 45.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.00) earnings per share. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on RCUS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, October 8th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Finally, The Goldman Sachs Group boosted their target price on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arcus Biosciences has an average rating of “Moderate Buy” and a consensus price target of $28.89.

Institutional Trading of Arcus Biosciences

Several institutional investors have recently added to or reduced their stakes in RCUS. JPMorgan Chase & Co. raised its stake in shares of Arcus Biosciences by 5.4% in the third quarter. JPMorgan Chase & Co. now owns 63,942 shares of the company’s stock worth $870,000 after purchasing an additional 3,280 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Arcus Biosciences by 39.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,120,062 shares of the company’s stock valued at $15,233,000 after buying an additional 314,757 shares during the last quarter. Vestal Point Capital LP bought a new stake in Arcus Biosciences in the 3rd quarter worth about $3,400,000. Public Employees Retirement System of Ohio purchased a new position in Arcus Biosciences in the 3rd quarter worth about $299,000. Finally, Parkman Healthcare Partners LLC raised its position in Arcus Biosciences by 8.9% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 652,680 shares of the company’s stock worth $8,876,000 after buying an additional 53,070 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.